

Nuedexta
Effective 11/26/18

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Pseudobulbar affect (PBA) is a condition that's characterized by episodes of sudden uncontrollable and inappropriate laughing or crying. PBA typically occurs in people with certain neurological conditions or injuries, which might affect the way the brain controls emotion.

Nuedexta® (dextromethorphan hydrobromide/quinidine sulfate) is a combination product containing dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 agonist) and quinidine sulfate (a CYP450 2D6 inhibitor) indicated for the treatment of Pseudobulbar affect (PBA).

Coverage Guidelines

Authorization may be granted for members with a diagnosis or indication for the treatment of Pseudobulbar Affect (PBA) due to a neurological condition (e.g., amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease).

Limitations

1. Initial approvals will be for 12 months.
2. A quantity limit of 60 capsules per month applies.

References

1. <https://www.mayoclinic.org/diseases-conditions/pseudobulbar-affect/diagnosis-treatment>. 2018 May.
2. Nuedexta (dextromethorphan/quinidine) [prescribing information]. Aliso Viejo, CA: Avanir Pharmaceuticals; January 2016.



3. Dextromethorphan and Quinidine. Lexi-Interact [database online]. Hudson, OH: Lexicomp Inc; 2015. <http://online.lexi.com>. Accessed April 14, 2015.
4. Cummings JL, Lyketsos CG, Raskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242-1254.[PubMed 26393847]10.1001/jama.2015.10214

Review History

11/28/11 – Reviewed
01/03/12 – Effective
11/26/12 – Reviewed
12/01/12 – Updated (RxAuth implementation)
11/25/13 – Reviewed
11/24/14 – Reviewed
11/27/17 – Reviewed in P&T Meeting
11/26/18 – Updated

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.